Document is current
Any future updates will be listed below
-
Authors
Wegen, Simone https://orcid.org/0000-0002-0361-728X
Claus, Karina
Linde, Philipp
Rosenbrock, Johannes
Trommer, Maike
Zander, Thomas
Tuchscherer, Armin
Bruns, Christiane
Schlößer, Hans Anton
Schröder, Wolfgang
Eich, Marie-Lisa
Fischer, Thomas
Schomäcker, Klaus
Drzezga, Alexander
Kobe, Carsten
Roth, Katrin Sabine
Weindler, Jasmin Josefine
-
Funding
Funding for this research was provided by:
Universitätsklinikum Köln
- License Information
-
More Information
Article History
Received: 3 December 2023
Accepted: 8 March 2024
First Online: 4 April 2024
Change Date: 20 May 2024
Change Type: Update
Change Details: Name of 16th author was wronly tagged in xml-file.
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent: Informed consent to undergo imaging and radiotherapy was obtained from all individual participants included in the study. The local institutional review board waived requirement to obtain consent for retrospective data analysis (23-1254-retro).
: This study has been supported by SOFIE by the provision of precursors for [<sup>68</sup>Ga]Ga-FAPI-46 synthesis. AD discloses research support from Siemens Healthineers, Life Molecular Imaging, GE Healthcare, AVID Radiopharmaceuticals, SOFIE and Eisai; Speaker Honorary and/or Advisory Boards fees from Siemens Healthineers, Sanofi, GE Healthcare, Biogen, Novo Nordisk; Invicro Stock from Siemens Healthineers, Lantheus Holding and a patent pending for <sup>18</sup>F-PSMA7 (PSMA-PET imaging tracer). HS discloses funding for research by Astra Zeneca and Tabby therapeutics and honoraries for advisory boards from BMS. All others have nothing to disclose.
: Disclosure of potential conflicts of interest: This study has been supported by SOFIE by the provision of precursors for [68Ga]Ga-FAPI-46 synthesis. AD discloses research support from Siemens Healthineers, Life Molecular Imaging, GE Healthcare, AVID Radiopharmaceuticals, SOFIE and Eisai; Speaker Honorary and/or Advisory Boards fees from Siemens Healthineers, Sanofi, GE Healthcare, Biogen, Novo Nordisk; Invicro Stock from Siemens Healthineers, Lantheus Holding and a patent pending for 18 F-PSMA7 (PSMA-PET imaging tracer). HS discloses funding for research by Astra Zeneca and Tabby therapeutics and honoraries for advisory boards from BMS. All others have nothing to disclose.
